RZLT
Rezolute, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 27.46K | $127,433 | n/a | n/a |
| Q2 2026 | 64 | +3 | 50.24M | $261.09M | +9 | −6 |
| Q1 2026 | 63 | +7 | 53.20M | $162.23M | +14 | −7 |
| Q4 2025 | 56 | +1 | 61.70M | $145.62M | +3 | −2 |
| Q3 2025 | 14 | +1 | 31.48M | $295.95M | +2 | −1 |
| Q2 2025 | 10 | 0 | 26.66M | $118.90M | +2 | −2 |
| Q1 2025 | 7 | -1 | 3.87M | $11.23M | n/a | −1 |
| Q4 2024 | 8 | 0 | 4.74M | $23.24M | n/a | n/a |
| Q3 2024 | 7 | +1 | 2.88M | $13.99M | +1 | n/a |
| Q2 2024 | 6 | n/a | 2.25M | $9.69M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 1.05M | n/a | $4.50M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 353.70K | n/a | $1.52M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 337.53K | n/a | $1.45M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 315.85K | n/a | $1.36M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 180.42K | n/a | $775,810 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 17.65K | n/a | $75,899 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 124 holders, 86.21M shares, $263.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.